Scientists at The University of Toledo investigating improvements to a commonly used chemotherapy drug have discovered an entirely new class of cancer-killing agents that show promise in eradicating cancer stem cells.
Their findings could prove to be a breakthrough in not only treating tumors, but ensuring cancer doesn’t return years later — giving peace of mind to patients that their illness is truly gone.
“Not all cancer cells are the same, even in the same tumor,” said Dr. William Taylor, a professor in the Department of Biological Sciences in the UToledo College of Natural Sciences and Mathematics. “There is a lot of variability and some of the cells, like cancer stem cells, are much nastier. Everyone is trying to figure out how to kill them, and this may be one way to do it.”
Taylor and Dr. L.M. Viranga Tillekeratne, a professor in the Department of Medicinal and Biological Chemistry in the UToledo College of Pharmacy and Pharmaceutical Sciences, reported their findings in a paper recently published in the journal Scientific Reports.
Cancer stem cells are an intriguing target for researchers because of their potential to re-seed tumors.
When doctors remove a tumor surgically or target it with chemotherapy drugs or radiation therapy, the cancer may appear to be gone. However, evidence suggests that a tiny subpopulation of adaptable cancer cells can remain and circulate through the body to seed new metastasis in far-off locations.
Those cancer stem cells, Taylor said, are similar to dandelions in a well-manicured lawn.
“You could chop the plant off, but it will drop a seed. You know the seeds are there, but they’re hiding,” he said. “You pull one weed out and another comes up right after it. Cancers can be like this as well.”
The small molecule they have isolated appears to lock on to those stem cells and kill them by blocking their absorption of an amino acid called cystine.
UToledo was awarded a patent for the discovery late last year.
For Tillekeratne and Taylor, uncovering a new class of therapeutic molecules could prove to be an even larger contribution to cancer research than the project they initially envisioned.
“At present, there are no drugs that can kill cancer stem cells, but people are looking for them,” Tillekeratne said. “A lot of drugs are discovered by serendipity. Sometimes in research if you get unexpected results, you welcome that because it opens up a new line of research. This also shows the beauty of collaboration. I wouldn’t have been able to do this on my own, and [Taylor] wouldn’t have been able to do it on his own.”
Tillekeratne has received a three-year, $449,000 grant from the National Institutes of Health National Cancer Institute to continue testing the effectiveness of the newly identified therapy.
Because the molecules so selectively target cancer stem cells, it’s possible they could ultimately be paired with other chemotherapy drugs to deliver a more comprehensive treatment.
However, the researchers have found their agents show stand-alone promise in treating sarcomas and a subtype of breast cancer known as claudin-low breast cancer, which represents up to 14 percent of all breast cancers and can be particularly difficult to treat.
The Latest on: Cancer-killing agents
via Google News
The Latest on: Cancer-killing agents
- Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestoneson January 12, 2021 at 1:46 am
RP2; New data to be reported in 2021 in combination with Opdivo in Phase 1 all comers study WOBURN, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology ...
- Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestoneson January 11, 2021 at 4:13 am
In October 2020, Replimune presented positive data from the single agent RP2 portion of the clinical ... intended to improve the direct cancer-killing effects of selective virus replication ...
- Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestoneson January 10, 2021 at 4:00 pm
Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor ...
- GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE(TM) REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENTon December 21, 2020 at 9:07 pm
Prior to being treated with TriKE™ GTB-3550, the HR-MDS patient failed hypomethylating agent (HMA) and Luspatercept therapies ... activates and harnesses the patient's native NK cell's cancer killing ...
- GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550 TriKE™ REDUCES CANCER CELLS BY 61.7% FOR A HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) PATIENTon December 21, 2020 at 8:15 am
Prior to being treated with TriKE™ GTB-3550, the HR-MDS patient failed hypomethylating agent (HMA ... the patient's native NK cell's cancer killing ability in a target-directed fashion without ...
- With Pierre Fabre Deal, Cellectar Shifts Strategy Under New CEOon December 15, 2020 at 4:00 pm
Cellectar on Wednesday announced it will work with French drug company Pierre Fabre to develop cancer treatments that combine “cytotoxics”—cancer-killing agents—produced by Pierre Fabre ...
- Carcinoma News and Researchon December 2, 2020 at 4:00 pm
Solove Research Institute described a potential therapeutic anticancer vaccine that frees suppressed cancer-killing immune cells ... a broad-spectrum antifungal agent that has been shown to ...
- The Evolution of Cancer Researchon September 22, 2020 at 6:42 pm
“Being adaptable is the main advantage of immuno-oncology agents over other cancer therapies ... In essence, ADCs combine a cancer-killing payload and an antibody that binds to a specific ...
- Israeli Scientists Develop "Micro Missile" to Combat Canceron July 30, 2019 at 5:10 pm
"The cancer-killing molecules work only where they are ... improve the efficacy and safety of chemotherapy agents. These new anti-cancer molecules are currently in the pre-clinical stage with ...
via Bing News